List of Descovy drug patents
Descovy is owned by Gilead Sciences Inc.
Descovy contains Emtricitabine; Tenofovir Alafenamide Fumarate.
Descovy has a total of 7 drug patents out of which 1 drug patent has expired.
Expired drug patents of Descovy are:
- US7803788
Descovy was authorised for market use on 04 April, 2016.
Descovy is available in tablet;oral dosage forms.
Descovy can be used as prophylaxis of hiv-1 infection; treatment of hiv-1 infection; treatment of hiv infection, treatment of hiv infection; prophylaxis of hiv-1 infection; treatment of hiv-1 infection, treatment of hiv-1 infection.
The generics of Descovy are possible to be released after 15 February, 2033.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7390791 | GILEAD SCIENCES INC | Prodrugs of phosphonate nucleotide analogues |
Apr, 2025
(2 years from now) | |
| US8754065 | GILEAD SCIENCES INC | Tenofovir alafenamide hemifumarate |
Aug, 2032
(9 years from now) | |
| US9296769 | GILEAD SCIENCES INC | Tenofovir alafenamide hemifumarate |
Aug, 2032
(9 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7803788 | GILEAD SCIENCES INC | Prodrugs of phosphonate nucoleotide analogues |
Feb, 2022
(1 year, 4 days ago) | |
|
US7390791
(Pediatric) | GILEAD SCIENCES INC | Prodrugs of phosphonate nucleotide analogues |
Oct, 2025
(2 years from now) | |
|
US9296769
(Pediatric) | GILEAD SCIENCES INC | Tenofovir alafenamide hemifumarate |
Feb, 2033
(10 years from now) | |
|
US8754065
(Pediatric) | GILEAD SCIENCES INC | Tenofovir alafenamide hemifumarate |
Feb, 2033
(10 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity (ODE) | Sep 28, 2024 |
| New Indication (I) | Oct 3, 2022 |
Drugs and Companies using EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE ingredient
Market Authorisation Date: 04 April, 2016
Treatment: Treatment of hiv-1 infection; Prophylaxis of hiv-1 infection; Treatment of hiv infection
Dosage: TABLET;ORAL
availability in other generic markets.
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic